Subject: Specialty Quantity Limit Inqovi 4006-H P2023

Drug

INQOVI  (decitabine and cedazuridine)

Policy:

      I.  PROGRAM DESCRIPTION

          The standard limit is designed to allow a quantity sufficient for
          the most common uses of the medication. The recommended
          dosing parameters for the treatment of all FDA-approved
          indications fall within the standard limits. Coverage of an
          additional quantity may be reviewed on a case-by-case basis
          upon request.

   II.  COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Inqovi    (decitabine/cedazuridine)   35mg/100mg tablets	5 tablets   per 28 days	•  One tablet orally once daily on days 1       through 5 of each 28-day cycle   •  Dose reductions may be necessary due      to adverse effects.

 

Place of Service:

Outpatient

The above policy is based on the following references:

1. Inqovi [package insert]. Princeton, NJ: Taiho Oncology Inc.; March 2022.

Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

June 18, 2023